Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 - Marketscreener.com - WorldWideWatchers

Innoviva Specialty Therapeutics Positive Phase 3 Oral Zoliflodacin Data for the Treatment of Uncomplicated Gonorrhea Announced at ESCMID Global 2024 – Marketscreener.com

Post author:datasapiens
Post published:April 26, 2024
Post category:data and network analysis

Published on: 2024-04-24